Thomas Jaenisch
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Zika Virus Infection | 27 | 2024 | 101 | 6.350 |
Why?
| Dengue | 25 | 2024 | 65 | 5.830 |
Why?
| Zika Virus | 23 | 2024 | 76 | 4.030 |
Why?
| Pregnancy Complications, Infectious | 12 | 2022 | 334 | 2.290 |
Why?
| Disease Outbreaks | 9 | 2024 | 333 | 1.700 |
Why?
| Microcephaly | 9 | 2023 | 57 | 1.610 |
Why?
| Dengue Virus | 12 | 2024 | 41 | 1.190 |
Why?
| Epidemics | 4 | 2023 | 79 | 1.150 |
Why?
| Communicable Diseases | 6 | 2024 | 143 | 1.040 |
Why?
| Seroepidemiologic Studies | 15 | 2024 | 157 | 0.990 |
Why?
| Malaria | 3 | 2022 | 54 | 0.980 |
Why?
| Antibodies, Viral | 14 | 2024 | 607 | 0.860 |
Why?
| Congenital Abnormalities | 2 | 2021 | 75 | 0.830 |
Why?
| Chikungunya Fever | 8 | 2024 | 73 | 0.830 |
Why?
| Brazil | 15 | 2024 | 102 | 0.830 |
Why?
| Malaria, Falciparum | 3 | 2012 | 29 | 0.800 |
Why?
| Protein Array Analysis | 2 | 2020 | 56 | 0.790 |
Why?
| Masks | 1 | 2022 | 61 | 0.780 |
Why?
| Endpoint Determination | 2 | 2018 | 76 | 0.750 |
Why?
| Anemia | 3 | 2022 | 155 | 0.710 |
Why?
| Public Health | 4 | 2024 | 498 | 0.710 |
Why?
| Dengue Vaccines | 2 | 2018 | 9 | 0.670 |
Why?
| Epitopes, B-Lymphocyte | 1 | 2019 | 17 | 0.630 |
Why?
| Severe Dengue | 5 | 2022 | 10 | 0.610 |
Why?
| Latin America | 8 | 2024 | 83 | 0.580 |
Why?
| Humans | 84 | 2025 | 129705 | 0.570 |
Why?
| Plasmodium falciparum | 3 | 2019 | 33 | 0.560 |
Why?
| Clinical Trials as Topic | 2 | 2018 | 1008 | 0.550 |
Why?
| Parasitemia | 2 | 2021 | 11 | 0.530 |
Why?
| Child Health | 1 | 2016 | 145 | 0.470 |
Why?
| Capital Financing | 1 | 2013 | 7 | 0.450 |
Why?
| Prospective Studies | 16 | 2023 | 7130 | 0.440 |
Why?
| Peptides | 1 | 2019 | 903 | 0.420 |
Why?
| Young Adult | 22 | 2024 | 12363 | 0.400 |
Why?
| Politics | 2 | 2025 | 90 | 0.400 |
Why?
| Child | 25 | 2024 | 20963 | 0.390 |
Why?
| Genetic Variation | 2 | 2017 | 936 | 0.380 |
Why?
| Chikungunya virus | 6 | 2023 | 73 | 0.380 |
Why?
| Mosquito Vectors | 4 | 2019 | 23 | 0.370 |
Why?
| Sexual Partners | 2 | 2024 | 191 | 0.370 |
Why?
| Biomedical Research | 2 | 2016 | 656 | 0.370 |
Why?
| Female | 40 | 2024 | 68561 | 0.360 |
Why?
| Emergency Responders | 2 | 2021 | 36 | 0.360 |
Why?
| Bayes Theorem | 2 | 2022 | 367 | 0.340 |
Why?
| Aedes | 4 | 2019 | 57 | 0.340 |
Why?
| Hemoglobins | 2 | 2022 | 344 | 0.330 |
Why?
| Infectious Disease Transmission, Vertical | 2 | 2021 | 167 | 0.330 |
Why?
| Pregnancy | 13 | 2022 | 6273 | 0.330 |
Why?
| Alphavirus | 2 | 2019 | 20 | 0.330 |
Why?
| Adolescent | 21 | 2024 | 20355 | 0.330 |
Why?
| Delivery of Health Care | 1 | 2016 | 904 | 0.320 |
Why?
| Alphavirus Infections | 2 | 2019 | 44 | 0.320 |
Why?
| Causality | 3 | 2024 | 114 | 0.310 |
Why?
| Serologic Tests | 4 | 2021 | 49 | 0.300 |
Why?
| Asia | 5 | 2023 | 62 | 0.300 |
Why?
| Adult | 26 | 2024 | 35595 | 0.300 |
Why?
| Male | 31 | 2024 | 63544 | 0.290 |
Why?
| Viremia | 3 | 2024 | 133 | 0.290 |
Why?
| Incidence | 7 | 2020 | 2658 | 0.270 |
Why?
| Immunity, Humoral | 2 | 2019 | 121 | 0.270 |
Why?
| Infant, Newborn | 12 | 2022 | 5752 | 0.270 |
Why?
| Virus Diseases | 2 | 2019 | 211 | 0.270 |
Why?
| Infant | 11 | 2021 | 9097 | 0.260 |
Why?
| Pneumonia | 1 | 2012 | 613 | 0.260 |
Why?
| Cluster Analysis | 2 | 2019 | 482 | 0.260 |
Why?
| Meta-Analysis as Topic | 2 | 2024 | 168 | 0.250 |
Why?
| Sexually Transmitted Diseases, Viral | 2 | 2024 | 8 | 0.240 |
Why?
| Child, Preschool | 14 | 2024 | 10565 | 0.240 |
Why?
| Middle Aged | 17 | 2024 | 31103 | 0.240 |
Why?
| Africa South of the Sahara | 2 | 2022 | 46 | 0.230 |
Why?
| Mass Media | 1 | 2025 | 42 | 0.230 |
Why?
| Fever | 2 | 2023 | 301 | 0.230 |
Why?
| Malaria Vaccines | 2 | 2019 | 11 | 0.230 |
Why?
| Viral Nonstructural Proteins | 2 | 2018 | 58 | 0.230 |
Why?
| Arbovirus Infections | 1 | 2024 | 18 | 0.230 |
Why?
| Arboviruses | 2 | 2024 | 11 | 0.230 |
Why?
| South America | 1 | 2024 | 56 | 0.220 |
Why?
| Severity of Illness Index | 2 | 2014 | 2783 | 0.220 |
Why?
| Semantics | 1 | 2024 | 100 | 0.220 |
Why?
| Attitude of Health Personnel | 1 | 2011 | 1092 | 0.210 |
Why?
| Linear Models | 2 | 2023 | 823 | 0.210 |
Why?
| Molecular Diagnostic Techniques | 2 | 2021 | 97 | 0.210 |
Why?
| O'nyong-nyong Virus | 2 | 2019 | 4 | 0.210 |
Why?
| Risk Factors | 10 | 2022 | 9832 | 0.200 |
Why?
| Information Dissemination | 1 | 2025 | 207 | 0.200 |
Why?
| Toxoplasmosis | 2 | 2019 | 37 | 0.200 |
Why?
| Oligohydramnios | 1 | 2022 | 11 | 0.200 |
Why?
| Antibodies, Neutralizing | 2 | 2022 | 260 | 0.200 |
Why?
| Ebolavirus | 1 | 2022 | 34 | 0.200 |
Why?
| RNA, Viral | 4 | 2022 | 622 | 0.200 |
Why?
| Mosquito Control | 2 | 2014 | 25 | 0.200 |
Why?
| Cytokines | 3 | 2021 | 2008 | 0.200 |
Why?
| Personal Protective Equipment | 1 | 2022 | 55 | 0.200 |
Why?
| Vietnam | 4 | 2024 | 25 | 0.200 |
Why?
| Research Design | 3 | 2024 | 1048 | 0.200 |
Why?
| Algorithms | 2 | 2022 | 1632 | 0.200 |
Why?
| Observational Studies as Topic | 1 | 2022 | 110 | 0.190 |
Why?
| World Health Organization | 4 | 2018 | 109 | 0.190 |
Why?
| Endemic Diseases | 3 | 2024 | 32 | 0.190 |
Why?
| Cohort Studies | 8 | 2025 | 5410 | 0.190 |
Why?
| Tanzania | 2 | 2012 | 44 | 0.180 |
Why?
| Epitopes | 2 | 2020 | 468 | 0.180 |
Why?
| Pandemics | 4 | 2025 | 1526 | 0.180 |
Why?
| Health Policy | 2 | 2014 | 364 | 0.180 |
Why?
| Chemokine CXCL10 | 1 | 2021 | 33 | 0.180 |
Why?
| Epitope Mapping | 1 | 2020 | 59 | 0.170 |
Why?
| Risk | 5 | 2021 | 871 | 0.170 |
Why?
| Prevalence | 4 | 2021 | 2557 | 0.170 |
Why?
| Transients and Migrants | 1 | 2020 | 24 | 0.170 |
Why?
| Rubella virus | 1 | 2019 | 6 | 0.170 |
Why?
| Parvovirus B19, Human | 1 | 2019 | 3 | 0.170 |
Why?
| Emigration and Immigration | 1 | 2020 | 50 | 0.170 |
Why?
| Case-Control Studies | 4 | 2021 | 3363 | 0.170 |
Why?
| Toxoplasma | 1 | 2019 | 39 | 0.160 |
Why?
| Hospitalization | 2 | 2020 | 2091 | 0.160 |
Why?
| Biomarkers | 5 | 2023 | 3893 | 0.160 |
Why?
| Hydrocephalus | 1 | 2020 | 104 | 0.160 |
Why?
| Diagnosis, Differential | 3 | 2021 | 1442 | 0.160 |
Why?
| Phylogeny | 3 | 2019 | 864 | 0.160 |
Why?
| Antibodies, Protozoan | 1 | 2019 | 33 | 0.160 |
Why?
| Violence | 1 | 2021 | 236 | 0.160 |
Why?
| Viral Load | 1 | 2021 | 449 | 0.160 |
Why?
| Africa | 2 | 2019 | 102 | 0.160 |
Why?
| Cytomegalovirus | 1 | 2019 | 159 | 0.160 |
Why?
| Automation | 1 | 2019 | 82 | 0.150 |
Why?
| Premature Birth | 1 | 2022 | 313 | 0.150 |
Why?
| Peptide Library | 1 | 2019 | 87 | 0.150 |
Why?
| Communicable Diseases, Emerging | 1 | 2018 | 30 | 0.150 |
Why?
| Serotyping | 1 | 2018 | 31 | 0.150 |
Why?
| Genotype | 4 | 2017 | 1836 | 0.150 |
Why?
| Global Health | 3 | 2019 | 333 | 0.150 |
Why?
| Serum | 1 | 2018 | 57 | 0.150 |
Why?
| Phosphoinositide Phospholipase C | 1 | 2017 | 5 | 0.140 |
Why?
| C-Reactive Protein | 1 | 2020 | 394 | 0.140 |
Why?
| Maternal-Fetal Exchange | 1 | 2018 | 159 | 0.140 |
Why?
| Delphi Technique | 1 | 2018 | 219 | 0.140 |
Why?
| Nucleic Acid Amplification Techniques | 1 | 2017 | 36 | 0.140 |
Why?
| Longitudinal Studies | 4 | 2022 | 2670 | 0.140 |
Why?
| Peptide Mapping | 1 | 2017 | 62 | 0.140 |
Why?
| Blood Donors | 1 | 2018 | 97 | 0.140 |
Why?
| Sequence Homology | 1 | 2016 | 40 | 0.130 |
Why?
| Caribbean Region | 3 | 2020 | 22 | 0.130 |
Why?
| Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 828 | 0.130 |
Why?
| Histocompatibility Antigens Class I | 1 | 2017 | 196 | 0.130 |
Why?
| Viral Envelope Proteins | 1 | 2016 | 86 | 0.120 |
Why?
| Clinical Protocols | 1 | 2016 | 259 | 0.120 |
Why?
| Antigens | 1 | 2017 | 346 | 0.120 |
Why?
| Serogroup | 3 | 2021 | 30 | 0.120 |
Why?
| Antibodies | 1 | 2017 | 392 | 0.120 |
Why?
| Fluid Therapy | 1 | 2016 | 140 | 0.120 |
Why?
| Antigens, Viral | 2 | 2018 | 181 | 0.120 |
Why?
| Models, Theoretical | 1 | 2018 | 551 | 0.120 |
Why?
| Reproducibility of Results | 2 | 2019 | 3054 | 0.110 |
Why?
| Residence Characteristics | 1 | 2017 | 327 | 0.110 |
Why?
| European Union | 1 | 2013 | 10 | 0.110 |
Why?
| Environment | 1 | 2016 | 348 | 0.110 |
Why?
| Animals | 11 | 2019 | 34733 | 0.110 |
Why?
| Mental Health | 1 | 2020 | 676 | 0.110 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2021 | 829 | 0.100 |
Why?
| Immunoglobulin M | 3 | 2021 | 270 | 0.100 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 784 | 0.100 |
Why?
| Disease Management | 1 | 2016 | 596 | 0.100 |
Why?
| Peru | 2 | 2021 | 54 | 0.090 |
Why?
| Sensitivity and Specificity | 4 | 2019 | 1849 | 0.090 |
Why?
| Follow-Up Studies | 3 | 2021 | 4939 | 0.090 |
Why?
| Virology | 1 | 2010 | 23 | 0.090 |
Why?
| Reagent Kits, Diagnostic | 1 | 2010 | 44 | 0.090 |
Why?
| Mass Screening | 1 | 2018 | 1130 | 0.090 |
Why?
| Indian Ocean Islands | 1 | 2010 | 1 | 0.090 |
Why?
| Inflammation | 1 | 2021 | 2705 | 0.090 |
Why?
| Cross Reactions | 2 | 2022 | 130 | 0.090 |
Why?
| Neutralization Tests | 2 | 2021 | 74 | 0.080 |
Why?
| Age Factors | 2 | 2020 | 3145 | 0.080 |
Why?
| Family Characteristics | 2 | 2021 | 176 | 0.080 |
Why?
| Rural Health | 1 | 2010 | 71 | 0.080 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2017 | 2071 | 0.080 |
Why?
| Kinetics | 2 | 2024 | 1620 | 0.080 |
Why?
| Age Distribution | 1 | 2010 | 380 | 0.080 |
Why?
| Americas | 2 | 2019 | 19 | 0.080 |
Why?
| Sexual Behavior | 2 | 2024 | 483 | 0.080 |
Why?
| Focus Groups | 1 | 2011 | 456 | 0.080 |
Why?
| Coinfection | 2 | 2019 | 133 | 0.080 |
Why?
| Multivariate Analysis | 1 | 2012 | 1507 | 0.080 |
Why?
| Surveys and Questionnaires | 2 | 2011 | 5396 | 0.070 |
Why?
| Genome, Viral | 2 | 2019 | 131 | 0.070 |
Why?
| Spatio-Temporal Analysis | 2 | 2017 | 27 | 0.070 |
Why?
| Risk Assessment | 1 | 2017 | 3297 | 0.070 |
Why?
| Antigens, Protozoan | 1 | 2007 | 27 | 0.070 |
Why?
| High-Throughput Screening Assays | 2 | 2020 | 134 | 0.070 |
Why?
| Prenatal Care | 2 | 2019 | 273 | 0.070 |
Why?
| Logistic Models | 1 | 2012 | 1980 | 0.070 |
Why?
| Immunoglobulin G | 2 | 2021 | 842 | 0.070 |
Why?
| Urbanization | 2 | 2019 | 25 | 0.070 |
Why?
| Microsatellite Repeats | 1 | 2007 | 163 | 0.070 |
Why?
| Aged | 6 | 2023 | 22113 | 0.060 |
Why?
| Tropical Climate | 2 | 2016 | 18 | 0.060 |
Why?
| Biosurveillance | 1 | 2024 | 1 | 0.060 |
Why?
| Common Data Elements | 1 | 2024 | 11 | 0.060 |
Why?
| Platelet Count | 1 | 2024 | 85 | 0.060 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2022 | 1379 | 0.060 |
Why?
| Europe | 1 | 2025 | 370 | 0.060 |
Why?
| Polymorphism, Genetic | 1 | 2007 | 643 | 0.060 |
Why?
| Bangladesh | 1 | 2023 | 45 | 0.050 |
Why?
| Checklist | 1 | 2024 | 100 | 0.050 |
Why?
| Altitude | 1 | 2007 | 451 | 0.050 |
Why?
| Data Interpretation, Statistical | 1 | 2024 | 338 | 0.050 |
Why?
| Guidelines as Topic | 1 | 2024 | 261 | 0.050 |
Why?
| Burkina Faso | 1 | 2021 | 4 | 0.050 |
Why?
| Middle East | 1 | 2021 | 11 | 0.050 |
Why?
| Colostrum | 1 | 2021 | 4 | 0.050 |
Why?
| Venezuela | 1 | 2021 | 7 | 0.050 |
Why?
| Publication Bias | 1 | 2021 | 37 | 0.050 |
Why?
| Pregnant Women | 1 | 2022 | 127 | 0.050 |
Why?
| Pregnancy Trimesters | 1 | 2021 | 16 | 0.050 |
Why?
| Amniotic Fluid | 1 | 2021 | 79 | 0.050 |
Why?
| Microspheres | 1 | 2021 | 123 | 0.050 |
Why?
| Colorado | 2 | 2021 | 4471 | 0.040 |
Why?
| Blood | 1 | 2021 | 99 | 0.040 |
Why?
| Immunoassay | 1 | 2021 | 104 | 0.040 |
Why?
| Disease Progression | 2 | 2020 | 2612 | 0.040 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 328 | 0.040 |
Why?
| Immunomodulation | 1 | 2021 | 90 | 0.040 |
Why?
| Parturition | 1 | 2020 | 66 | 0.040 |
Why?
| Cross-Sectional Studies | 2 | 2021 | 5050 | 0.040 |
Why?
| Pregnancy Outcome | 1 | 2022 | 379 | 0.040 |
Why?
| Disease Reservoirs | 1 | 2019 | 19 | 0.040 |
Why?
| Pilot Projects | 1 | 2025 | 1567 | 0.040 |
Why?
| Retrospective Studies | 3 | 2024 | 14669 | 0.040 |
Why?
| Clinical Laboratory Techniques | 1 | 2020 | 97 | 0.040 |
Why?
| Geography, Medical | 1 | 2019 | 11 | 0.040 |
Why?
| Genes, Viral | 1 | 2019 | 94 | 0.040 |
Why?
| Zoonoses | 1 | 2019 | 28 | 0.040 |
Why?
| Pathology, Molecular | 1 | 2019 | 26 | 0.040 |
Why?
| Primates | 1 | 2019 | 120 | 0.040 |
Why?
| Polymerase Chain Reaction | 1 | 2021 | 1047 | 0.040 |
Why?
| Computer Simulation | 1 | 2022 | 947 | 0.040 |
Why?
| Bolivia | 1 | 2018 | 63 | 0.040 |
Why?
| Aged, 80 and over | 2 | 2021 | 7074 | 0.040 |
Why?
| Viral Plaque Assay | 1 | 2017 | 30 | 0.040 |
Why?
| Volunteers | 1 | 2018 | 33 | 0.040 |
Why?
| Basic Reproduction Number | 1 | 2017 | 5 | 0.040 |
Why?
| Time Factors | 2 | 2020 | 6593 | 0.040 |
Why?
| Parent-Child Relations | 1 | 2020 | 254 | 0.040 |
Why?
| Betacoronavirus | 1 | 2020 | 266 | 0.040 |
Why?
| Iron | 1 | 2019 | 285 | 0.040 |
Why?
| Poliovirus Vaccines | 1 | 2017 | 3 | 0.030 |
Why?
| Binding Sites, Antibody | 1 | 2017 | 42 | 0.030 |
Why?
| Culicidae | 1 | 2017 | 30 | 0.030 |
Why?
| Molecular Epidemiology | 1 | 2017 | 63 | 0.030 |
Why?
| Cell Surface Display Techniques | 1 | 2017 | 11 | 0.030 |
Why?
| Climate Change | 1 | 2019 | 160 | 0.030 |
Why?
| Phylogeography | 1 | 2017 | 49 | 0.030 |
Why?
| Antibody Specificity | 1 | 2017 | 185 | 0.030 |
Why?
| Adaptation, Psychological | 1 | 2021 | 612 | 0.030 |
Why?
| Comorbidity | 1 | 2021 | 1545 | 0.030 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 962 | 0.030 |
Why?
| Bacterial Infections | 1 | 2018 | 240 | 0.030 |
Why?
| Capsid Proteins | 1 | 2017 | 91 | 0.030 |
Why?
| Pacific Islands | 1 | 2015 | 2 | 0.030 |
Why?
| Enterovirus | 1 | 2017 | 78 | 0.030 |
Why?
| Inpatients | 1 | 2020 | 456 | 0.030 |
Why?
| HEK293 Cells | 1 | 2018 | 673 | 0.030 |
Why?
| Immunization | 1 | 2018 | 423 | 0.030 |
Why?
| Models, Statistical | 1 | 2019 | 632 | 0.030 |
Why?
| Hospitals | 1 | 2020 | 635 | 0.030 |
Why?
| Coronavirus Infections | 1 | 2020 | 355 | 0.030 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2015 | 137 | 0.030 |
Why?
| Travel | 1 | 2015 | 123 | 0.030 |
Why?
| Shock | 1 | 2016 | 99 | 0.030 |
Why?
| Blood Vessels | 1 | 2016 | 184 | 0.030 |
Why?
| Capillary Permeability | 1 | 2014 | 141 | 0.030 |
Why?
| Amino Acid Sequence | 1 | 2017 | 2051 | 0.030 |
Why?
| Quality Control | 1 | 2013 | 156 | 0.030 |
Why?
| Rain | 1 | 2013 | 45 | 0.030 |
Why?
| Antiviral Agents | 1 | 2018 | 709 | 0.030 |
Why?
| Computational Biology | 1 | 2017 | 588 | 0.030 |
Why?
| Cell Line | 1 | 2018 | 2768 | 0.020 |
Why?
| Thrombocytopenia | 1 | 2014 | 187 | 0.020 |
Why?
| Prognosis | 1 | 2020 | 3801 | 0.020 |
Why?
| Antibodies, Monoclonal | 1 | 2018 | 1360 | 0.020 |
Why?
| Genome-Wide Association Study | 1 | 2017 | 1334 | 0.020 |
Why?
| Temperature | 1 | 2013 | 634 | 0.020 |
Why?
| Hemorrhage | 1 | 2014 | 697 | 0.020 |
Why?
| Vaccination | 1 | 2017 | 1362 | 0.020 |
Why?
| United States | 1 | 2025 | 14078 | 0.020 |
Why?
| Merozoite Surface Protein 1 | 1 | 2007 | 4 | 0.020 |
Why?
| Databases, Factual | 1 | 2013 | 1297 | 0.020 |
Why?
| Zimbabwe | 1 | 2007 | 54 | 0.020 |
Why?
| Protozoan Proteins | 1 | 2007 | 75 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2014 | 1529 | 0.020 |
Why?
| Mutation | 1 | 2017 | 3674 | 0.020 |
Why?
| Treatment Outcome | 1 | 2018 | 10299 | 0.010 |
Why?
|
|
Jaenisch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|